Breaking Finance News

A statement released earlier today by Ladenburg Thalmann about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) bumps the target price to $31.00

Boasting a price of $19.16, Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) traded 0.00% even on the day. With the last stock price close up 17.05% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Bellicum Pharmaceuticals Inc has recorded a 50-day average of $18.69 and a two hundred day average of $16.37. Volume of trade was down over the average, with 0 shares of BLCM changing hands under the typical 276,205

Ladenburg Thalmann bumped up the target of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to $31.00 stating a potential upside of 0.62%.

Performance Chart

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

With a total market value of $0, Bellicum Pharmaceuticals Inc has with a one year low of $7.24 and a one year high of $23.84 .

A total of 5 equity analysts have released a ratings update on BLCM. Two equity analysts rating the company a strong buy, one equity analyst rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $20.40.

Brief Synopsis About Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company's CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.